Treatment of congestive heart failure has changed dramatically during the past 20 years, but diuretic drugs remain an essential component. Diuretics are essential despite the fact that these drugs stimulate the renin-angiotensin-aldosterone (RAA) axis and lead to adaptive responses that may be counterproductive. In this paper, new diuretic drugs and new uses of older drugs are discussed. These approaches emphasize low-dose combination therapy and may prove superior to traditional approaches that rely exclusively on loop diuretics. Such approaches aim to prevent adverse compensatory processes that appear to result from chronic diuretic treatment. These include acute and chronic increases in plasma renin activity and stimulation of the sympathetic nervous system, both of which increase afterload and may tend to increase mortality. They also include adaptive changes in nephron structure and function resulting from diuretic-induced increases in distal sodium load and diuretic-induced neurohormonal stimulation. These adaptations blunt the effectiveness of diuretic therapy. Diuretic strategies that rely on combinations of diuretics are emphasized as a method to prevent resistance. If diuretic resistance does develop, higher-dose combination regimens, continuous diuretic infusions and mechanical ultrafiltration can be used to overcome diuretic adaptations and restore diuretic efficacy. The goal of reducing the extracellular fluid volume with the least stimulation of the RAA axis and minimal changes in nephron architecture can be achieved in many patients.

Keywords:
Loop diuretics, Thiazides, Sodium, Edema
1.
Odemuyiwa O, Gilmartin J, Kenny D, Hall RJ: Captopril and the diuretic requirements in moderate and severe chronic heart failure. Eur Heart J 1989;10:586–590.
2.
Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ: Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356:615–620.
3.
Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996;78:902–907.
4.
Brater DC, Anderson SA, Brown-Cartright D: Response to furosemide in chronic renal insufficiency: Rationale for limited doses. Clin Pharmacol Ther 1986;40:134–139.
5.
Stroupe KT, Forthofer MM, Brater DC, Murray MD: Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmacoeconomics 2000;17:429–440.
6.
Ellison DH: Diuretic resistance: Physiology and therapeutics. Semin Nephrol 1999;19:581–597.
7.
Heird WC, Dell RB, Driscoll JM Jr, Grebin B, Winters RW: Metabolic acidosis resulting from intravenous alimentation mixtures containing synthetic amino acids. N Engl J Med 1972;287:943–948.
8.
Frölich JC, Hollifield JW, Dormois JC, Frölich BL, Seyberth H, Michelakis AM, Oates JA: Suppression of plasma renin activity by indomethacin in man. Circ Res 1976;39:447–452.
9.
Martínez-Maldonado M, Gely R, Tapia E, Benabe JE: Role of macula densa in diuretics-induced renin release. Hypertension 1990;16:261–268.
10.
Modena B, Holmer S, Eckardt KU, Schricker K, Riegger G, Kaissling B, Kurtz A: Furosemide stimulates renin expression in the kidneys of salt-supplemented rats. Pflügers Arch 1993;424:403–409.
11.
Knauf H, Mutschler E: Functional state of the nephron and diuretic dose-response – Rationale for low-dose combination therapy. Cardiology 1994;84(suppl 2):18–26.
12.
Northridge DB, Newby DE, Rooney E, Norrie J, Dargie HJ: Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and furosemide in the treatment of patients with chronic heart failure. Am Heart J 1999;138:1149–1157.
13.
Grantham JJ, Chonko AM: The physiological basis and clinical use of diuretics; in Brenner BM, Stein JH (eds): Sodium and Water Homeostasis, ed 1. New York, Churchill Livingstone, 1978, pp 178–211.
14.
Wilcox CS, Mitch WE, Kelly RA, Skorecki K, Meyer TW, Friedman PA, Souney PF: Response of the kidney to furosemide. 1. Effects of salt intake and renal compensation. J Lab Clin Med 1983;102:450–458.
15.
Walter SJ, Shirley DG: The effect of chronic hydrochlorothiazide administration on renal function in the rat. Clin Sci (Lond) 1986;70:379–387.
16.
Ellison DH, Velázquez H, Wright FS: Adaptation of the distal convoluted tubule of the rat: Structural and functional effects of dietary salt intake and chronic diuretic infusion. J Clin Invest 1989;83:113–126.
17.
Kaissling B, Bachmann S, Kriz W: Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment. Am J Physiol 1985;248:F374–F381.
18.
Kaissling B, Stanton BA: Adaptation of distal tubule and collecting duct to increased sodium delivery. 1. Ultrastructure. Am J Physiol 1988;255:F1256–F1268.
19.
Scherzer P, Wald H, Popovtzer MM: Enhanced glomerular filtration and Na+-K+-ATPase with furosemide administration. Am J Physiol 1987;252:F910–F915.
20.
Wald H, Scherzer P, Popovtzer MM: Inhibition of thick ascending limb Na+-K+-ATPase activity in salt-loaded rats by furosemide. Am J Physiol 1989;256:F549–F555.
21.
Chen ZF, Vaughn DA, Beaumont K, Fanestil DD: Effects of diuretic treatment and of dietary sodium on renal binding of 3H-metolazone. J Am Soc Nephrol 1990;1:91–98.
22.
Obermüller N, Bernstein PL, Velázquez H, Reilly R, Moser D, Ellison DH, Bachmann S: Expression of the thiazide-sensitive Na-Cl cotransporter in rat and human kidney. Am J Physiol 1995;269:F900–F910.
23.
Abdallah JG, Schrier RW, Edelstein C, Jennings SD, Wyse BD, Ellison DH: Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(–)-cotransporter abundance: role of aldosterone. J Am Soc Nephrol 2001;12:1335–1341.
24.
Loon NR, Wilcox CS, Unwin RJ: Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 1989;36:682–689.
25.
Almeshari K, Ahlstrom NG, Capraro FE, Wilcox CS: A volume-independent component to postdiuretic sodium retention in humans. J Am Soc Nephrol 1993;3:1878–1883.
26.
Chemtob S, Doray J-L, Laudignon N, Papageorgiou A, Varma DR, Aranda JV: Alternating sequential dosing with furosemide and ethacrynic acid in drug tolerance in the newborn. Am J Dis Child 1989;143:850–854.
27.
Epstein M, Lepp BA, Hoffman DS, Levinson R: Potentiation of furosemide by metolazone in refractory edema. Curr Ther Res 1977;21:656–667.
28.
Oster JR, Epstein M, Smoler S: Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention. Ann Intern Med 1983;99:405–406.
29.
Oimomi M, Takase S, Saeki S: Combination diuretic therapy for severe refractory nephrotic syndrome. Lancet 1990;336:1004–1005.
30.
Ellison DH: The physiologic basis of diuretic synergism: Its role in treating diuretic resistance. Ann Intern Med 1991;114:886–894.
31.
Marone C, Muggli F, Lahn W, Frey FJ: Pharmacokinetic and pharmacodynamic interaction between furosemide and metolazone in man. Eur J Clin Invest 1985;15:253–257.
32.
Okusa MD, Persson AEG, Wright FS: Chlorothiazide effect on feedback-mediated control of glomerular filtration rate. Am J Physiol 1989;257:F137–F144.
33.
Ellison DH, Velázquez H, Wright FS: Thiazide-sensitive sodium chloride cotransport in early distal tubule. Am J Physiol 1987;253:F546–F554.
34.
Garin EH: A comparison of combinations of diuretics in nephrotic edema. Am J Dis Child 1987;141:769–771.
35.
Channer KS, McLean KA, Lawson-Matthew P, Richardson M: Combination diuretic treatment in severe heart failure: A randomised controlled trial. Br Heart J 1994;71:146–150.
36.
Fliser D, Schröter M, Neubeck M, Ritz E: Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 1994;46:482–488.
37.
Garg LC, Narang N: Effects of hydrochlorothiazide on Na-K-ATPase activity along the rat nephron. Kidney Int 1987;31:918–922.
38.
Morsing P, Velázquez H, Wright FS, Ellison DH: Adaptation of distal convoluted tubule of rats. 2. Effects of chronic thiazide infusion. Am J Physiol 1991;261:F137–F143.
39.
Miller PD, Berns AS: Acute metabolic alkalosis perpetuating hypercarbia: A role for acetazolamide in chronic obstructive pulmonary disease. JAMA 1977;238:2400–2401.
40.
Vargo DL, Brater DC, Rudy DW, Swan SK: Dopamine does not enhance furosemide-induced natriuresis in patients with congestive heart failure. J Am Soc Nephrol 1996;7:1032–1037.
41.
Gerlag PGG, van Meijel JJM: High-dose furosemide in the treatment of refractory congestive heart failure. Arch Intern Med 1988;148:286–291.
42.
Rybak LP: Ototoxicity of loop diuretics. Otolaryngol Clin North Am 1993;26:829–844.
43.
Nierenberg DW: Furosemide and ethacrynic acid in acute tubular necrosis. West J Med 1980;133:163–170.
44.
Dikshit K, Vyden JK, Forrester JS, Chatterjee K, Prakash R, Swan HJC: Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med 1973;288:1087–1090.
45.
Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine B, Cohn JN: Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Ann Intern Med 1985;103:1–6.
46.
Curran KA, Hebert MJ, Cain BD, Wingo CS: Evidence for the presence of a K-dependent acidifying adenosine triphosphatase in the rabbit renal medulla. Kidney Int 1992;42:1093–1098.
47.
Goldsmith SR, Francis G, Cohn JN: Attenuation of the pressor response to intravenous furosemide by angiotensin converting enzyme inhibition in congestive heart failure. Am J Cardiol 1989;64:1382–1385.
48.
Leslie D, Gheorghiade M: Is there a role for thiamine supplementation in the management of heart failure? Am Heart J 1996;131:1248–1250.
49.
Shimon I, Almog S, Vered Z, Seligmann H, Shefi M, Peleg E, Rosenthal T, Motro M, Halkin H, Ezra D: Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy. Am J Med 1995;98:485–490.
50.
Rudy DW, Voelker JR, Greene PK, Esparza FA, Brater DC: Loop diuretics for chronic renal insufficiency: A continuous infusion is more efficacious than bolus therapy. Ann Intern Med 1991;115:360–366.
51.
Lahav M, Regev A, Ra’anani P, Thodor E: Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest 1992;102:725–731.
52.
Van Meyel JJM, Smits P, Dormans T, Gerlag PGG, Russel FGM, Gribnau FWJ: Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance. J Intern Med 1994;235:329–334.
53.
Magovern JA, Magovern GJ Jr: Diuresis in hemodynamically compromised patients: Continuous furosemide infusion. Ann Thorac Surg 1990;50:482–484.
54.
Agostoni P, Marenzi G, Lauri G, Perego G, Schianni M, Sganzerla P, Guazzi MD: Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: Failure of furosemide to provide the same result. Am J Med 1994;96:191–199.
55.
Brater DC: Diuretic pharmacokinetics and pharmacodynamics; in Seldin DW, Giebisch G (eds): Diuretic Agents: Clinical Physiology and Pharmacology. San Diego, Academic Press, 1997, pp 189–208.
56.
Brater DC: Diuretic therapy. N Engl J Med 1998;339:387–395.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.